Valneva
Valneva SE, a prominent biotechnology company headquartered in France, is dedicated to developing and commercialising innovative vaccines for infectious diseases. Founded in 2013, Valneva has rapidly established itself in the global vaccine industry, with significant operations across Europe and North America. The company focuses on creating unique vaccine solutions, including its flagship product, the inactivated vaccine for Lyme disease, which stands out for its advanced technology and efficacy. Valneva's commitment to addressing unmet medical needs has positioned it as a key player in the market, achieving notable milestones such as partnerships with leading pharmaceutical firms and successful clinical trials. With a strong emphasis on research and development, Valneva continues to drive advancements in vaccine technology, contributing to global health initiatives.
DitchCarbon Score
How does Valneva's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Valneva's score of 37 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Valneva's reported carbon emissions
In 2024, Valneva reported total carbon emissions of approximately 59,000,000 kg CO2e, with emissions distributed across various scopes: 1,277,000 kg CO2e from Scope 1, 2,499,000 kg CO2e from Scope 2, and a significant 55,534,000 kg CO2e from Scope 3. The Scope 3 emissions include substantial contributions from purchased goods and services (approximately 34,964,000 kg CO2e) and upstream transportation and distribution (about 9,044,000 kg CO2e). Valneva has made notable strides in reducing its carbon footprint, achieving a 48% reduction in CO2 emissions from gas and electricity since 2019, equating to a decrease of 1,630 tonnes CO2e. This reduction is attributed to a shift towards green electricity. Looking ahead, the company has set ambitious targets to further reduce its CO2 emissions from laboratories and manufacturing sites by 50% from a 2022 baseline by 2030, covering both Scope 1 and Scope 2 emissions. Valneva's commitment to sustainability is evident in its ongoing initiatives and reduction targets, positioning the company as a proactive player in addressing climate change within the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2024 | |
|---|---|
| Scope 1 | 1,277,000 |
| Scope 2 | 2,499,000 |
| Scope 3 | 55,534,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Valneva is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
